WallStSmart

DaVita HealthCare Partners Inc (DVA)vsThe Joint Corp (JYNT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 24327% more annual revenue ($13.84B vs $56.64M). JYNT leads profitability with a 5.7% profit margin vs 5.7%. DVA appears more attractively valued with a PEG of 0.65. DVA earns a higher WallStSmart Score of 70/100 (B-).

DVA

Strong Buy

70

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 5.5
Piotroski: 3/9Altman Z: 1.22

JYNT

Hold

47

out of 100

Grade: D+

Growth: 6.0Profit: 5.5Value: 3.0Quality: 6.5
Piotroski: 6/9Altman Z: 0.86
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DVASignificantly Overvalued (-17.0%)

Margin of Safety

-17.0%

Fair Value

$123.34

Current Price

$192.16

$68.82 premium

UndervaluedFair: $123.34Overvalued

Intrinsic value data unavailable for JYNT.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVA4 strengths · Avg: 9.0/10
Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

Debt/EquityHealth
-17.5010/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.658/10

Growing faster than its price suggests

EPS GrowthGrowth
43.5%8/10

Earnings expanding 43.5% YoY

JYNT3 strengths · Avg: 8.7/10
Return on EquityProfitability
20.9%9/10

Every $100 of equity generates 21 in profit

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

EPS GrowthGrowth
43.8%8/10

Earnings expanding 43.8% YoY

Areas to Watch

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
5.7%3/10

5.7% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

JYNT4 concerns · Avg: 2.5/10
Market CapQuality
$118.18M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
5.7%3/10

5.7% margin — thin

PEG RatioValuation
8.832/10

Expensive relative to growth rate

P/E RatioValuation
92.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : DVA

The strongest argument for DVA centers on Return on Equity, Debt/Equity, PEG Ratio. PEG of 0.65 suggests the stock is reasonably priced for its growth.

Bull Case : JYNT

The strongest argument for JYNT centers on Return on Equity, Debt/Equity, EPS Growth. Revenue growth of 13.3% demonstrates continued momentum.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Bear Case : JYNT

The primary concerns for JYNT are Market Cap, Profit Margin, PEG Ratio. A P/E of 92.1x leaves little room for execution misses.

Key Dynamics to Monitor

JYNT carries more volatility with a beta of 1.10 — expect wider price swings.

JYNT is growing revenue faster at 13.3% — sustainability is the question.

DVA generates stronger free cash flow (219M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DVA scores higher overall (70/100 vs 47/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

The Joint Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Joint Corp. The company is headquartered in Scottsdale, Arizona.

Visit Website →

Want to dig deeper into these stocks?